Why Is MCKESSON CORP (MCK) Stock Up Today?

MCK stock surged 6.14% to $906.27 on October 1, 2026, driven by the announcement that the company extended its pharmaceutical distribution agreements with CVS Health. The move was interpreted as a clearing event for industry peers, according to BofA, and signaled continued stability in MCK’s core operations. The stock opened at $852.99 and reached an intraday high of $924.21 before settling near $901.78 in late trading. Volume remained subdued at 0.1 million shares, below the 3-month average.

What Happened

McKesson announced an agreement to extend its distribution contracts with CVS Health, a development described as a positive catalyst for the company’s business continuity. The deal reaffirmed the strength of MCK’s relationship with one of the largest pharmacy chains in the U.S. In addition, the company reiterated its FY27 adjusted EPS guidance of $44.20 to $45.00, aligning with its prior expectations and slightly below the $44.65 consensus. These updates provided clarity to investors and supported the stock’s upward momentum.

What The Data Shows

The stock’s performance came against a backdrop of mixed sentiment, with a 30-day average of 55/100 and a 7-day average of 50/100. The intraday session showed a sharp rally from the open, with the stock climbing over $50 in the first two hours of trading. MCK’s fundamentals remain mixed, with a P/E of 22.8 and a net margin of 1.1%. Recent insider transactions include three sales totaling $7.1 million, with the most recent filing on September 10. Meanwhile, several members of Congress have made small purchases in the stock over the past three months.

What To Watch

With no upcoming earnings scheduled, investors will likely monitor the breadth of coverage and any follow-up commentary from analysts. The stock’s ability to hold above $900 will also be a key technical indicator in the near term.